MDT's stock continues consolidating above its 52‑week high, reflecting strength in its vascular device segment. Revenue guidance and profit margin trends remain positive, supporting a bullish outlook.

Despite Jim Cramer’s bearish remarks on Medtronic, overall healthcare demand growth and MDT’s product breadth suggest a cautiously bullish stance. However, short‑term volatility remains a concern.

Long‑term projections for peripheral vascular devices indicate robust demand growth, aligning with MDT’s strategic advantage. Potential regulatory risks are limited by the company’s diversified pipeline.

Recent data shows MDT trading above both 20‑ and 50‑day moving averages, with increasing volume signaling continued upward momentum. The pattern aligns with a bullish technical setup.